Lipocine licenses TLANDO in Brazil; oral testosterone market grew 34% CAGR 2019-2023

Lipocine Inc.

Exclusive license and supply agreement with Aché Laboratórios for TLANDO in Brazil.
Lipocine receives upfront payment, plus regulatory milestones and royalties on net sales.
Aché is responsible for regulatory submission and approval in Brazil.
No oral testosterone therapy is currently registered in Brazil; market CAGR 34% 2019-2023.
TLANDO is FDA-approved for testosterone replacement therapy in adult males with hypogonadism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.